European Joint Programme on Rare Diseases (EJP RD) 1st Joint Call 2019: Translational research projects to accelerate diagnosis and/or explore disease progression and mechanisms of rare diseases

The aim of the Join Transitional Call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear benefit for patients. Projects shall involve a group of rare diseases or a single rare disease following the European definition i.e. a disease affecting not more than five in 10 000 persons in the European Community, EC associated states and Canada.

Scheme at a glance

EU co-funded
  • All
Career stage
  • Mid career
  • Senior career
Research area
  • Basic research
  • Health services research
  • Patient-oriented and clinical research
  • Population health research
Funding available The maximum funding for successful partner(s) from Republic of Ireland in this call is €370,000. It is anticipated one or two proposals will be funded.
Duration of funding 36 months

Additional Information

The research projects submitted within this call must be based on novel ideas stemming from consolidated previous results or preliminary data and must be clearly endowed with benefit for the patients, i.e. studies allowing a rapid implementation into public health-related decisions or into the clinics. To achieve this goal, the necessary expertise and resources should be brought together from academia, clinical/public health sector and private companies whenever relevant. The research teams within a consortium should include investigators from complementary scientific disciplines, research areas and expertise necessary to achieve the proposed objectives.

Transnational research proposals must cover at least one of the following areas, which are equal in relevance for this call:

A. Research to accelerate diagnosis, e.g:

  • New schemes for finding diagnosis for undiagnosed patients;
  • Improved annotation and interpretation of variants and development of diagnostic tests for the more prevalent variants;
  • Novel modalities of functional analysis of candidate variants through in vitro, cell, tissue or animal studies.
  • -omic or multi-omic integrated approaches for discovery of disease causes and mechanisms including development of relevant bioinformatic tools;

B. Research to explore disease progression and mechanisms, e.g:

  • Identification of clinical biomarkers, clinical outcome measures and surrogate endpoints;
  • Identification of novel pathophysiological pathways in appropriate disease models that effectively mimic the human condition.

This is a joint transnational call: applicants must apply as part of a transnational consortium.
Each consortium submitting a proposal must involve a minimum of four eligible and a maximum of six eligible partners from at least four different countries participating to the call (see list in the Guidance Notes). No more than two eligible partners from the same country participating in the call will be accepted in one consortium.

Lead Applicants from Republic of Ireland can apply from a recognised HRB Host Institution. If successful they will be funded by the Health Research Board up the maximum amount of the call.


Pre-proposals must be submitted electronically the EJP RD website ( Further details can be found in the call text and the HRB supplementary guidance notes.. The call is a two-step application, with a first stage (pre-proposal submission) deadline of 14 February 2019. Invitations to submit full proposals will be issued in early May 2019 with a full proposal submission deadline of 11 June 2019.


Dr Annalisa Montesanti
E amontesanti(at)
T 01-2345208

Opening date
10:00 14-12-2018
Closing date
17:00 15-02-2019
Early May 2019
Decision expected
November 2019
Next call expected
Q4 2019